Congratulations to Alicia Fisch, Kawasaki Disease Canada’s Student Research Award recipient! At a presentation in Toronto in April, Alicia shared an overview of her research, “Elastin-Derived Peptides in the Development of Kawasaki Disease”. Alicia’s research is supervised by Dr. Rae Yeung, Professor of Paediatrics, Immunology and Medical Science at the University of Toronto and the Senior Scientist in Cell Biology Research at The Hospital For Sick Children. You will need to stay tuned to learn about all Alicia’s findings as the research has yet to be published, but you can see an overview of it here: Alicia Fisch Research Summary April 22 2017
A research team from Yokohama City University has identified four types of protein that could be used to diagnose “Kawasaki disease” at an early stage. The discovery is important because it will hopefully lead to a reduction in heart complications that occasionally develop as a result of the illness.
Yokohama City University associate professor Yayoi Kimura and her team of fellow researchers observed that the concentration levels of four different proteins — LBP, LRG1, AGT and RBP4 — changed during the acute or early phase of Kawasaki disease.
These findings are significant because the disease is known for being difficult to diagnose during the acute stage. There are at least five prominent symptoms, such as fever, red eyes and rash. But because it takes between three to seven days for these symptoms to appear altogether, even experts hesitate to commence treatment before all the symptoms are there.
Therefore, in the future, if doctors are able to identify protein-level related changes during the acute phase of Kawasaki disease, it should facilitate an earlier diagnosis, and hence enable treatment to commence more quickly. In cases where symptoms persist for 10 days or so after onset, and are not treated, heart complications such as coronary artery disease can develop in 25 to 30 percent of patients.
Having made this discovery, Yokohama City University now intends to test a diagnostic agent in clinical trials from fiscal 2017 onward, in collaboration with a Japanese company, having already applied for an international patent. Looking ahead, Kimura is positive. “We are hoping that our findings can be used in four to five years time to make actual diagnoses.”
To read the full article, click here.
(January 2017) — Kawasaki disease (KD) is the leading cause of acquired heart disease in Canadian children. While some of the approximately 500 children diagnosed annually in Canada will have no lingering effects, some will develop lifelong heart problems. Recent publications by researchers located, primarily, at The Hospital for Sick Children in Toronto (SickKids) and at Centre Hospitalier Universitaire Ste. Justine (CHU-SJ) in Montreal, are beginning to peel back some of the mysteries surrounding Kawasaki disease, helping both patients and their families.
Click to read full article: January 2017 Canadian researchers bring new insights into Kawasaki disease and its consequences